<?xml version="1.0" encoding="UTF-8"?>
<ref id="B188-ijerph-17-05648">
 <label>188.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Michot</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Albiges</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Chaput</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Saada</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Pommeret</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Griscelli</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Balleyguier</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Besse</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Marabelle</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Netzer</surname>
    <given-names>F.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: A case report</article-title>
  <source>Ann. Oncol.</source>
  <year>2020</year>
  <volume>31</volume>
  <fpage>961</fpage>
  <lpage>964</lpage>
  <pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.300</pub-id>
  <pub-id pub-id-type="pmid">32247642</pub-id>
 </element-citation>
</ref>
